Vitrafy Life Sciences (ASX:VFY) ROC (Joel Greenblatt) %: -3,386.43% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:VFY Vitrafy Life Sciences Ltd ASX:VFY
5 GF Score
Price A$2.81
! 5 Warning Signs
View Full Analysis

What is Vitrafy Life Sciences ROC (Joel Greenblatt) %?

Vitrafy Life Sciences ASX:VFY -0.71% 5 ROC (Joel Greenblatt) % is -3,386.43% as of Dec. 2025. GuruFocus rates ASX:VFY with a GF Score™ of 5/100. The stock has 5 warning signs investors should review. Among 2,814 Software companies, Vitrafy Life Sciences ranks worse than 93.21% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vitrafy Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3,386.43%.

The historical rank and industry rank for Vitrafy Life Sciences's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:VFY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3916.06   Med: -1957.56   Max: 0.94
Current: -2676.8

During the past 4 years, Vitrafy Life Sciences's highest ROC (Joel Greenblatt) % was 0.94%. The lowest was -3916.06%. And the median was -1957.56%.

ASX:VFY's ROC (Joel Greenblatt) % is ranked worse than
93.21% of 2814 companies
in the Software industry
Industry Median: 20 vs ASX:VFY: -2676.80

Vitrafy Life Sciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Vitrafy Life Sciences  (ASX:VFY) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Vitrafy Life Sciences ROC (Joel Greenblatt) % Related Terms


Vitrafy Life Sciences ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Vitrafy Life Sciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrafy Life Sciences ROC (Joel Greenblatt) % Chart

Vitrafy Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
0.00 0.00 0.94 -3,916.06

Vitrafy Life Sciences Semi-Annual Data
Jun22 Jun23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial 0.00 0.00 -5,207.32 -2,122.84 -3,386.43

ASX:VFY vs MSFT, ORCL, PLTR: ROC (Joel Greenblatt) % Comparison

For the Software - Infrastructure subindustry, Vitrafy Life Sciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrafy Life Sciences ROC (Joel Greenblatt) % vs Software Industry

For the Software industry and Technology sector, Vitrafy Life Sciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Vitrafy Life Sciences's ROC (Joel Greenblatt) % falls into.


ASX:VFY
5GF Score
Vitrafy Life Sciences Ltd ASX:VFY
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrafy Life Sciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.058 + 0 + 0.983) - (0.775 + 1.428 + 0.431)
=-1.593

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.356 + 0 + 0) - (1.11 + 0 + 0.515)
=-1.269

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Vitrafy Life Sciences for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-18.964/( ( (0.593 + max(-1.593, 0)) + (0.527 + max(-1.269, 0)) )/ 2 )
=-18.964/( ( 0.593 + 0.527 )/ 2 )
=-18.964/0.56
=-3,386.43 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -3,386.43% mean?
Vitrafy Life Sciences (ASX:VFY) has a ROC (Joel Greenblatt) % of -3,386.43% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #2623 out of 2814 companies in the Software industry, placing it in the top 93.2%.
Is Vitrafy Life Sciences' ROC (Joel Greenblatt) % too high?
Vitrafy Life Sciences' current ROC (Joel Greenblatt) % is -3,386.43%. Based on the distribution chart, Vitrafy Life Sciences ranks #2623 out of 2814 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' ROC (Joel Greenblatt) % compare to MSFT and ORCL?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #2623 out of 2814 companies for ROC (Joel Greenblatt) %. This places Vitrafy Life Sciences in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 20.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Software company?
The median ROC (Joel Greenblatt) % among Software companies is 20.00, based on 2,814 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median ROC (Joel Greenblatt) % is 20.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current ROC (Joel Greenblatt) % is -3,386.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current ROC (Joel Greenblatt) % of -3,386.43%. The current ROC (Joel Greenblatt) % is -3,386.43%. Vitrafy Life Sciences' overall GF Score™ is 5/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current ROC (Joel Greenblatt) % is -3,386.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitrafy Life Sciences Business Description

Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
5GF Score

Get the complete analysis for ASX:VFY

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.81
Price